Europe’s Revised Biosimilars Guideline Allows Non-EU Data In Applications
This article was originally published in The Pink Sheet Daily
Executive Summary
Some data from a non-European version of a reference product can be used in biosimilar marketing applications, a revised overarching biosimilars guideline from European regulators says. It also notes interchangeability is a matter for individual European countries to decide.
You may also be interested in...
Merck’s Revised Biosimilar Strategy Poised To Deliver
The big pharma has five biosimilars in Phase III development with its partner Samsung Bioepis, and expects to file them for regulatory approval in 2015 and 2016.
EU Acceptance Of Foreign Comparators For Biosimilar Applications Will Boost Industry
The European Union has announced that it will accept a reference product for a biosimilar application from countries with robust regulatory systems and similar guidelines, a move that should significantly boost the domestic biosimilars industry.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.